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Psoriasis is a chronic inﬂammatory diseasemediated by a complex interplay between immune system and
keratinocytes. Initially considered as a keratinocyte proliferation/differentiation disorder, an immune
dysregulationwas conﬁrmed after the successful treatment of psoriasis with cyclosporine. The yingeyang
theory, or T helper type 1 (Th1)/Th2 concept, was then introduced to explain the rarity of atopic
dermatitis in patients with psoriasis and the aggravation of psoriasis after interferon-g treatment.
However, recent advances have revised the Th1/Th2 paradigm after the discovery of a novel subset of T
cells, called Th17 cells. Th17 cells produce interleukin (IL)-17 and IL-22, and have other important
downstream proinﬂammatory effects on skin, leading to clinical and pathological features typical of
psoriasis. Nowadays, emerging evidence suggests integrative and complicated inﬂammatory circuits
among Th1 and Th17 cells and keratinocytes in the pathogenesis of psoriasis, with Th17 cells playing
a central role. Herein, we review the biology of Th17 cells as well as the reciprocal interplay between Th17
and regulatory T cells in psoriasis. Integration of the IL-23/Th17 axis into a revised concept of psoriasis has
already been translated into novel therapeutic strategies. Studies investigating the effect and molecular
mechanism of conventional and biological therapy for psoriasis on the IL-23/Th17 pathway were also
discussed.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction: from Th1/Th2 to Th17
Traditionally, CD4þ T cells have classically been separated into two
dominant effector cell populations: T helper type 1 (Th1) and type 2
(Th2).1 However, during recent years, emerging studies, both in
mice and in human, have shown that interleukin (IL)-17-producing
T cells represents a new lineage of effector CD4 T cells, Th17 cells.2
IL-17 was ﬁrst identiﬁed in rodent T-cell hybridoma.3 Later, IL-23
was shown to mediate the expansion of IL-17-producing cells,
and the ﬁnding led to the discovery of Th17 cells.4e6 The concept of
Th17 cells as a distinct subset of T cells was further strengthened by
the delineation of its unique differentiation pathway. Differentia-
tion of naïve T cells into Th17 cells depends on a mechanism that is
different from the signals driving the development of Th1 [T-bet,
signal transducer and activator of transcription (STAT) 4, and
STAT1] and Th2 cells [GATA-binding protein 3 (GATA3), c-MAF, and
STAT6]. Interferon-g (IFN-g), as well as IL-12 and IL-4, drives naïve T
cells intoTh1 and Th2 responses separately, whereas IFN-g and IL-4y, National Taiwan University
an. Tel.: þ886 2 23562141;
iwanese Dermatological Associatiopotently inhibit the development of murine Th17 cells.2,7 Langrish
et al5 showed that proliferation of Th17 cells highly depends on IL-
23. Data presented by Dong8 and Murphy et al9 indicated that
inducible T-cell costimulator and IL-23 were required for IL-17
expression, but not for IFN-g expression, in the mice models of
experimental autoimmune encephalomyelitis and collagen-
induced arthritis. Like Th1 and Th2 cells, Th17 cells produce
a group of distinctive cytokines. Th17 cells do not produce IFN-g or
IL-4; instead, they produce IL-17 and express the IL-23 receptor (IL-
23R).5,7 Additionally, chemokine (C-C motif) receptor (CCR)4 and
CCR6 are major chemokine receptors involved in Th17 response,
which are different from predominant expression of CXCR6, CCR5,
and CXCR3 in Th1 cells as well as CCR3, CCR4, and CCR8 in Th2 cells,
respectively.10 Based on the unique priming cytokines, lineage-
speciﬁc transcriptional regulators, cytokine products, and cyto-
kine receptors, Th17 cells are widely accepted as a separate and
early lineage of effector T cells, rather than cells differentiating
directly from Th1 or Th2 cells.
Basics of Th17
A signiﬁcant amount of both clinical and experimental data has
established Th17 cells as a new lineage of Th cells. Differentiation ofn. Published by Elsevier Taiwan LLC. All rights reserved.
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costimulatory molecules and cytokines that mediate the develop-
ment of a speciﬁc Th-cell lineage in response to antigens. Although
IL-23 was originally shown to be important for the proliferation of
Th17 cells, compelling scientiﬁc evidence suggested that IL-23
alone was not sufﬁcient for the initiation of Th17 differentiation
from naïve T cells as they did not express IL-23R.5,11,12 A concomi-
tant presence of transforming growth factor-b (TGF-b) and at least
one proinﬂammatory cytokine, such as IL-6, IL-1b, IL-23, or IL-21,
was necessary for the differentiation of naïve T cells to Th17
cells.13e15 After induction by TGF-b and proinﬂammatory cytokines,
differentiating and differentiated Th17 cells upregulate the
expressions of IL-23R and IL-1R1, which may mediate or maintain
the ﬁnal lineage speciﬁcation or induce the proliferation of pre-
committed Th17 cells. Additionally, Langrish et al5 and Park et al7
showed that IL-23 had little effect on fully differentiated Th1 or Th2
cells, and Th1 or Th2 development apparatus (IFN-g, STAT1, and IL-
4) inhibited the development of Th17 cells. Mature Th17 cells were
resistant to suppression by Th1 or Th2 cytokines.5,7 These studies
suggest that the differentiation of CD4þ T cells to Th17 cells starts at
a point preceding commitment to the Th1 or Th2 lineages.
Integrated signals from cytokine receptors, T-cell receptors, and
costimulatory molecules lead to the expression lineage-speciﬁc
transcription factors that contribute signiﬁcantly to the differenti-
ation of different Th cells. Transcription factors and their regulators
T-bet, H2.0-like homeobox, STAT1, and STAT4 specify Th1 cell fate,
whereas GATA3, c-MAF, STAT6 govern Th2 cell differentiation.8
Neither the transcriptional factors implicated in Th1 differ-
entiationnor those in Th2 differentiation were involved in Th17 cell
development. Recently, two transcriptional factors, retinoid-related
orphan receptor (ROR) gt and RORa, were shown to play key roles in
the differentiation program of Th17 cells.16,17 TGF-b and IL-6 induce
the expression of RORgt and RORa in a STAT3-dependent manner.
STAT3protein regulates Th17differentiation, at least inpart, through
the induction of lineage-speciﬁc transcription factors and IL-23 also
signals through STAT3 in Th17 cells.18,19 On the contrary, RORgt-
deﬁcient T cells were defective in Th17 cell differentiation.16,18,20
Mice with RORgt-deﬁcient T cells lack tissue-inﬁltrating Th17 cells
and have attenuated autoimmune diseases.16 In addition to ROR, IFN
regulatory factor 4,21 runt-related transcription factor 1,22 and ATF-
like basic leucine zipper transcription factor23were also shown tobe
essential for Th17 cell differentiation.
Cytokines produced and secreted by Th17 cells include IL-6, IL-
17A, IL-17F, IL-21, IL-22, and tumor necrosis factor (TNF)-a.8 IL-17
family, for which the Th17 cells lineage is named, consists of six
cytokines (IL-17AeF).IL-17A, IL-17B, IL-17C, and IL17F, but not IL-
17E, have proinﬂammatory properties, can induce cytokines such
as TNF and IL-1b, and promote neutrophil migration.24 Although
Th17 cells are the major source of IL-17A, it can be produced by
a wide range of cell types, including CD8þ cells, gd-TCRþ cells,
neutrophils, B cells, and natural killer T cells.25e29 Functional
analysis of IL-17A has suggested that it plays an important and
unique role in the development of autoimmunity, inﬂammation,
tumors, and host protection against speciﬁc pathogens, such as
Candida,30 Mycobacterium,6 and Klebsiella.31 IL-17F shares 50%
sequence homology with IL-17A and is mainly involved in mucosal
host defense mechanism.24 Although the ability of IL-17B, IL-17C,
and IL-17D to express proinﬂammatory cytokines is similar to that
of IL-17A and IL-17F, the role of the former in the immune system
has not yet been fully elucidated.24 IL-17E is not produced by Th17
cells but produced by Th2 cells, cecal patch CD4þ and CD8þ T cells,
mast cells, and eosinophils.24 It enhances Th2 cell immune
response by inducing IL-4, IL-5, IL-13, IgE production, and eosino-
philia, contributing to the host defense against nematodes and
allergic disorders.24Circumstantial evidence also suggests that Th17 cells regulate
the development of autoimmune diseases, such as psoriasis,
rheumatoid arthritis, multiple sclerosis, inﬂammatory bowel
disease, and asthma.5,8,32 Emerging data also investigate the role of
Th17 cells in the etiopathogenesis of periodontal disease.33 In 1998,
Teunissen et al34 showed detectable levels of IL-17 mRNA in
lesional psoriatic skin, but not in nonlesional skin. Subsequent
studies also demonstrated increased expression of IL-17A, IL-17C,
IL-17F, and IL-23 subunits in lesional psoriatic skin compared with
nonlesional and normal skin.35 Kagami et al36 demonstrated that
circulating Th17, Th22, and Th1 cells were increased in psoriasis
patients, and blood levels of Th17 and Th1 cells also decreased after
therapy with TNF-a antagonist (inﬂiximab). Intradermal injection
of IL-23 in mice led to lesions with histopathological features
resembling psoriasis.37 CD4þ Th17 cells were present in higher
numbers in psoriatic lesions than in healthy skin and decreased
after treatment.38 Zaba et al39 showed that psoriatic dermal
dendritic cells could induce T-cell proliferation, and polarize T cells
to become Th17 and Th1 cells. Both IL-17A and IL-22 induce kera-
tinocyte expressing chemokine (C-C motif) ligand 20 (CCL20),
which attracts Th17 cells to sites of inﬂammation via CCL20eCCR6
signaling and drives epidermal acanthosis, linking the IL23/Th17
axis with pathology of psoriasis.40 Furthermore, human genetic
studies have shown multiple IL-17-related genes, including IL-23A,
IL-23R, IL-12B, TNFAIP3, and tyrosine kinase 2 (TYK2), as risk alleles
for psoriasis.41,42 IL-23A and IL-23R are speciﬁc to IL-23 signaling,
and TYK2 is a signal kinase downstream of IL-12 and IL-23. TNFAIP3
functions as a key regulator of NF-kB pathway, which is also the
downstream target of IL-17 receptor signaling. IL-12B gene
expresses the shared IL-12/23p40 subunit with IL-23.42 Collectively,
these data have conﬁrmed the central role of IL23/Th17 in the
pathogenesis of psoriasis.
IL-21 is not only a Th17 cytokine but also a differentiation factor
for Th17 cells when present alone or with IL-6 or TGF-b.18 Loss of IL-
21 or its receptor had decreased Th17 cells in mice, which resulted
in a large increase in T-regulatory cells (T-reg) in vitro.18,20,43
Additionally, IL-21 as well as TGF-b also acts in an autocrine
manner to promote Th17 differentiation.43e45
IL-23, a member of IL-12 family, is a heterodimeric cytokine
formed by a p40 chain, which is sharedwith IL-12, and a unique p19
chain. IL-23 is secreted by dendritic cells, macrophages, other
antigen-presenting cells as well as keratinocytes,46 and plays
a pivotal role in the survival and proliferation of Th17 cells after
priming with TGF-b and IL-6.5,9 In IL-23-deﬁcient mice, experi-
mental autoimmune encephalomyelitis resistance correlates with
the absence of IL-17-producing T cells.5
In addition to CD4þ Th cells, IL-17 can also be produced by
CD8þ T cells, called type 17 cytotoxic T cells (Tc17). Tc17 cells are
characterized by sharing some, but not all, phenotypical and
molecular features with both Th17 and Th1 cells. They express
Th17 population-selective features, such as CCR6, IL-23R, and
RORgt transcription factor.47 Ortega et al47 showed that Tc17
cells from psoriasis-inﬂamed skin tissue produced IL-17, IL-21,
and IL-22 (Th17-related cytokines) as well as TNF-a and IFN-g
(Th1-related cytokines). Tc17 cells also displayed T-cell
receptor/CD3-mediated cytotoxic abilities to kill target cells.47
Notably, when IL-12 was added to the Tc17 cell culture, the T-
bet (Th1-associated transcription factor) was clearly upregu-
lated.48 Recent studies have suggested that Tc17 cells also play
a role in the pathogenesis of psoriasis. Res et al49 reported that
psoriatic skin contained a T-cell inﬁltrate with a signiﬁcant
increased percentage of Tc17 cells compared to normal skin. The
increase of Tc17 cells was most pronounced in the psoriatic
epidermis, which reinforced the distinct functional role of Tc17
cells in psoriasis.49
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a unique subset of T lymphocytes, Th22, in patients with psoriasis.
Th22 cells are characterized by the secretion of IL-22, IL-10, and
TNF-a, but not IFN-g, IL-4, or IL-17.50 In contrast to Th17, predom-
inant expression of CCL20, IL-2, and RORgt was not seen in Th22
cells.16,48 Aryl hydrocarbon receptor is the key transcription factor
for Th22 differentiation.51,52 Fujita et al also showed that cutaneous
dendritic cells, particularly Langerhans cells, can induce the
differentiation of distinct IL-22-producing Th22 cells from naïve T
cells and peripheral T cells, with the help of IL-6 and TNF-a.51,53
Additionally, further studies showed that Th22 cells were
increased in psoriatic lesions51,52 and, like Th17 cells, showed an
epidermal homing characteristic.50 Th22-producing IL-22 ampli-
ﬁed TNF-a-induced signals, leading to a proinﬂammatory micro-
environment during skin immune reactions.50 These ﬁndings
implicated that Th22 may also contribute signiﬁcantly to the
pathogenesis of psoriasis.
Reciprocal relationship between Th17 and T-reg
Contribution of TGF-b to Th17 differentiation was initially viewed
with some surprise, as TGF-b induced FOXP3, which was consid-
ered as a transcription factor associated with the generation of
T-reg.54 T-reg plays an indispensable role in maintaining immu-
nological unresponsiveness to self-antigens and in suppressing
excessive immune responses deleterious to the host.55 However,
there are accumulating evidences that Th17 cells have evolved close
ties to T-reg cells. During homeostasis, the development of T-reg
cells seems to be favored in the presence of rich TGF-b and IL-2,
prompted by the cofactor all-trans retinoic acid.55e57 But TGF-
b directs naïve T cells toward Th17 differentiation when dendritic
cells are activated by microorganisms and produce IL-6 and IL-
23.13,39,55,58 Naïve T cells activated in the presence of TGF-b are
induced to express ROR or FOXP3, which engage in an antagonistic
competition with each other. FOXP3 can directly repress RORgt
and RORa at a high concentration of TGF-b, whereas addition of
cytokines, such as IL-6, IL-21, and IL-23, to low-concentration TGF-
b leads to upregulation of RORgt, which overrides the FOXP3-
mediated repression.59e61 Dominance of RORgt results in
commitment to Th17 cell lineage. Several groups also demonstrate
that the there is a developmental plasticity between Th17 and T-reg
cells.62e64 In certain inﬂammatory settings, FOXP3þ-induced T-reg
cells can be converted to Th17-type effector cells, but not the
reverse.62 IL-23 is the cytokine primarily responsible for this
conversion, which is likely mediated by high RORgt levels and
enhanced loss of FOXP3.62 Subsets of T cells that coexpress FOXP3
and RORgt have also been identiﬁed in vivo and ex vivo.59,65,66 This
discovery suggests that the conversion of T-reg toTh17 cell is not an
all-or-none transition, but a continuum of converting cells
exists.62e64 Further studies implicated the epigenetic regulation,
such as histone/protein deacetylation in the gene locus, as a key
factor for T-reg/Th17 conversion.67
Interplay between TNF and IL-17 in the pathogenesis of
psoriasis
The somewhat unexpected success of psoriasis treatment by TNF
blockers has established the role of TNF in the pathogenesis of
psoriasis unequivocally.68 TNF can be produced by different cells,
including keratinocytes, and Th1 and Th17 cell populations.68
Keratinocytes have both TNF-a and IL-17 receptors and can
produce inﬂammatory products on stimulation. TNF and IL-17
signaling share some common pathway, such as activation of NF-
kB. Previous studies suggest that TNF-a may serve as an indirect
activator of Th17 response through activating effects on myeloiddendritic cells.69,70 Additionally, in a recent study, TNF and IL-1 are
shown to further increase Th17 cell differentiation in the presence
of TGF-b and IL-6.13 Synergistic activation of some genes by IL-17
and TNF-a has also been found in osteoblasts, ﬁbroblasts, and
bone marrow stromal cells.71,72 Chiricozzi et al73 investigated the
complex interplay between IL-17 and TNF-a in psoriasis and indi-
cated that they ampliﬁed each other’s effect, both addictively and
synergistically. Their combined activity contributed to many of the
key inﬂammatory pathways in psoriasis.73 Consistent with these
ﬁndings, several groups showed that treatment with TNF-a antag-
onists suppressed synergistic TNF-a/IL-17 gene transcripts to
a greater extent than TNF-a “single-regulated” gene products.70,74e
76 Clinical response to TNF-a antagonists was correlated with early
reduction of IL-23 and IL-17A, followed by decreased Th1-
associated genes later.69,76
Effect of conventional agents on the IL23/Th17 axis in
psoriasis
The successful use ofmost conventional antipsoriasis treatmentwas
generally based on serendipity, and the exact mode of action was
often poorly understood. In this new era of IL23/Th17 in the path-
ogenesis of psoriasis, the effect of the conventional therapy deserves
further investigation. Racz et al77 evaluated the gene expression
frompatientswithpsoriasis and inmice prior to and after ultraviolet
B (UVB). They found that UVB exerted a suppressive effect on the
Th17 pathway via decreasing STAT3 phosphorylation in the
epidermis. A recent longitudinal study conducted by Coimbra et al78
also supported that bothUVB and psoralenplus ultraviolet A (PUVA)
treatment produced signiﬁcant reduction in theblood levels of IL-17,
IL-23, IL-22, TNF, IL-8, and vascular endothelial growth factor (VEGF)
in patients with psoriasis, which was consistent with clinical
improvement. Data presented by Haider et al showed that cyclo-
sporine A administration downregulated proinﬂammatory genes by
Th17 cells, including IL-17, IL-22, and downstream genes S100A12,
b-defensin-2, IL-1b, SEPRINB3, lipocalin 2, and CCL20, in the psoriatic
skin but not in peripheral blood.39,79,80 Recent investigations
showed that neither methotrexate nor acitretin was able to cause
signiﬁcant reduction in the blood levels of IL-23, IL-17, IL-22, and
Th17 cells in patients with rheumatoid arthritis.74,75,81 However, in
patients with psoriasis, Meephansan et al82 showed that metho-
trexate signiﬁcantly reduced serum level of IL-22 from 56.63 to 5.91
(p< 0.001) and therewas a positive correlation between IL-22 levels
and psoriasis area and severity index (PASI).
Biologics targeting IL-23/Th17 pathway
Based on the increased insight into the pathogenesis of psoriasis,
several new therapeutic approaches targeting the effector func-
tions of Th17 cells have been developed. Blocking of the IL-23/Th17
pathway can be achieved at different levels. Since IL-23 enhances
Th17 cell proliferation and IL-17 production, monoclonal antibodies
directed against p40, a shared subunit of IL-23 and IL-12, have
produced striking improvement in psoriasis patients. Leonardi
et al83 and Papp et al84 published the results of the PHOENIX 1 and
PHOENIX 2, phase III, randomized, placebo-controlled trials and
showed the efﬁcacy and safety of anti-p40 antibodies (ustekinu-
mab) in psoriasis. In PHOENIX 1, 171 (67.1%) and 170 (66.4%)
patients receiving ustekinumab 45 and 90 mg, respectively, ach-
ieved at least 75% improvement in PASI75 at Week 12.83 In
PHOENIX2, 273 (66.7%) and 311 (75.7%) patients treated with
ustekinumab 45 and 90 mg, respectively, achieved PASI75 at Week
12.84Recent studies have also demonstrated the long-term efﬁcacy
and safety of ustekinumab.85,86 High level of efﬁcacy of ustekinu-
mab was sustained through 5 years, and PASI75 responses were
Figure 1 Proposed schema of Th cell and regulatory T-cell differentiation. Dendritic cells load and present antigen and secrete mediators, leading to T-cell differentiation. Naïve
CD4þ T cells, after induction by dendritic cells, can differentiate to either Th (Th1, Th2, and Th17) cells or T-reg, depending on the lineage-speciﬁc priming cytokines and master
regulation transcription factors. Th17 cells require a combination of TGF-b and proinﬂammatory cytokines (IL-1B, IL-6, and IL-21) to differentiate from naïve T cells. STAT3, RORa,
and RORYt work together to establish Th17 cell transcriptional programs. However, the Th17 differentiation is inhibited by IFN-g and IL-4. Differentiated Th17 cells produce
proinﬂammatory cytokines and AMPS, leading to aberrant differentiation and proliferation of keratinocytes. AHR ¼ aryl hydrocarbon receptor ; AMP ¼ antimicrobial peptide;
IFN ¼ interferon; IL ¼ interleukin; GATA3 ¼ GATA-binding protein 3; ROR ¼ retinoid-related orphan receptor; STAT - signal transducer and activator of transcription;
TGF ¼ transforming growth factor; TH ¼ T helper cell, T-reg ¼ regulatory T cell; ¼ augmentation; ¼ inhibition; ¼ conversion.
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responses in 39.7% and 49.0% of those receiving ustekinumab 45
and 90 mg, respectively, at Week 244. The rates of adverse events
leading to discontinuation, severe adverse events, serious infec-
tions, nonmelanoma skin cancer, other malignancies, and
investigator-reported major adverse cardiovascular event per 100
patient-year of follow-up remained generally stable from Year 1
through Year 5.87 Additionally, similar efﬁcacy and safety proﬁle of
ustekinumab was achieved in a ustekinumab study involving Asian
population,88,89 despite known genetic polymorphism of psoriasis
among different ethnic groups,90 which might inﬂuence the effects
of some biologics for psoriasis treatment. In a controlled study
(ACCEPT), ustekinumab at a dose of 45 or 90 mg also showed
a superior effect than high-dose etanercept (50 mg twice weekly)
over a 12-week period in patients with psoriasis.91
Moreover, in mice deﬁcient in IL-17 receptor A, the formation of
imiquimod-induced skin lesions resembling psoriasis was
blocked.92 This discovery provided the evidence that cytokine-
targeting strategies aimed at blocking signal through IL-17
receptor might be beneﬁcial in the treatment of psoriasis. Several
clinical trials evaluated the efﬁcacy of monoclonal antibodies
against IL-17 [ixekizumab (LY2439821) and secukinumab (AIN
457)] and IL-17 receptor [brodalumab (AMG827)]. In three phase II
clinical trials, 81% of patients receiving subcutaneous secukinumab
150 mg (three or four doses) and 83% treated with secukinumab
10 mg/kg (three doses) achieved PASI75 at Week 12.93e95 Recent
data from a phase II study showed PASI75 response rates of 77%,
83%, and 82% following administration of subcutaneous ixekinu-
mab 25, 75, and 150 mg, respectively (Weeks 0, 2, 4, 8, and 12),
versus 7.7% for placebo at Week 12.96 Papp et al97 conducted
a phase II study assessing the efﬁcacy and safety of brodalumab,
and PASI75 response rates were observed in 33%, 77%, 82%, and 67%
of patients receiving brodalumab 70, 140, 210, and 280 mg,
respectively.IL-23, IL-17, TNF-a, IFN-g, and IL-12 all play important roles in
the immune response against speciﬁc pathogens.8,98 Since many
biologics disrupt the protective function of these cytokines, they
raise the possibility of increased risk of infection, such as tuber-
culosis, among psoriasis patients receiving therapy targeting TNF-
a and IL-23/Th17 signaling.8,98 Our studies supported using
Quantiferon-TB gold as a screening tool for latent tuberculosis
infection in psoriasis patients treated with TNF-a antagonists or
IL12/IL23 blockers, particularly in a tuberculosis endemic area
where bacille CalmetteeGuérin vaccination coverage is high.99,100
Conclusions
Compelling scientiﬁc evidences have established Th17 cells as key
players in causing psoriasis. Cytokines, including IL-23, IL-12, and
TNF-a, produced by activated myeloid dendritic cells after stimu-
lation by physical trauma or bacterial products drive naïve T cells to
undergo Th17 cells differentiation in the presence of TGF-b and IL-
6.13,39,46,58 The Th17 differentiation requires STAT3 activation and
expression of RORgt and RORa.16,19 Subsequently, proinﬂammatory
cytokines such as IL-17A, IL-17F, and IL-22 act on keratinocytes,
leading to aberrant differentiation and proliferation and to the
production of antimicrobial peptides, chemokines, and angiogenic
factors (Figure 1).40,101,102 These mediators are also able to recruit
and activate immune cells to the lesional skin and set up a positive
feedback loop, amplifying the core response.8,103 Taken together,
Th17cells, cytokines, and activated keratinocytes interact to estab-
lish an activated inﬂammatory network, ultimately leading to the
clinical features of psoriasis (Figure 1). With the advances in
understanding the immunopathogenesis of psoriasis, the treat-
ment of psoriasis has undergone a revolution. Therapeutic strate-
gies targeting the immunopathogenic pathway of Th17 provide
patients with therapies showing favorable therapeutic beneﬁts and
safety not previously seen in the treatment of psoriasis.
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